Sihuan Pharmaceutical (SEHK:460) Stock Price Lags Profit Recovery as Valuation Stretches

Sihuan Pharmaceutical Holdings Group entered these results following a period of weak share price performance, with the stock down over the past week, month and quarter, yet trading on a rich P/E of 21x. That is a set up for emotional trading. The headline from this half year is simple. Profitability has firmed up, with basic earnings per share at C¥0.0249 on revenue of C¥1,161.2m. The tug of war now is between investors who are concerned about the valuation strain and those who see a company that has moved into the black and is staying there.

Is Sihuan Pharmaceutical Holdings Group’s 21x P/E simply pricing in the move back to profit, or has the stock already run ahead of its fundamentals? Compare the rich multiple with the detailed valuation analysis for Sihuan Pharmaceutical Holdings Group

H1 2026 Earnings Summary

• Revenue (H1 2026 vs H1 2025): C¥1,161.2m vs. C¥1,146.2m
• Net Income (Excl. Extra Items, H1 2026 vs H1 2025): C¥224.7m vs. C¥102.6m
• Basic EPS (H1 2026 vs H1 2025): C¥0.0249 per share vs. C¥0.0111 per share
• Trailing 12-Month Net Income (Excl. Extra Items, to H1 2026 vs to H1 2025): C¥301.8m vs. a loss of C¥80.6m

Prefer clean charts instead of a dense wall of earnings figures and footnotes? View Sihuan Pharmaceutical Holdings Group’s full financial picture, including a clear presentation of its valuation, in the interactive company report for Sihuan Pharmaceutical Holdings Group.

Sihuan Pharmaceutical earnings tilt the story bullish

Sihuan Pharmaceutical shows a business that is holding revenue roughly steady while lifting profitability. Net income excluding extra items rose to C¥224.7m for the half, with basic EPS at C¥0.0249. Trailing 12 month net income moved from a prior loss into a C¥301.8m profit. That shift supports the idea that the diversified healthcare mix is now delivering more consistent earnings. For investors who see medical aesthetics and drug portfolios as growth themes, these results provide some grounding for a cautiously optimistic view of the business model.

Short term share pressure keeps the bear case alive

At the same time, Sihuan Pharmaceutical’s share price has fallen over the past 7, 30 and 90 days, which indicates that the market is still sceptical. Revenue is only modestly higher year on year, so the move into profit relies heavily on margin improvement that may not yet feel firmly established. For anyone concerned about execution across medical aesthetics, medicines and hospital services, this mixed picture keeps the risk narrative in play, even though the latest earnings do not point to immediate financial stress.

Compare the profit recovery story at Sihuan Pharmaceutical with what the street is pricing in at HK$0.82. To see whether analysts think this move into the black has further room to run, check the consensus price target analysis for Sihuan Pharmaceutical Holdings Group.

Stay Ahead With Simply Wall St

If Sihuan Pharmaceutical Holdings Group’s recent move into consistent profitability has caught your attention, register for free with Simply Wall St and add it to a Watchlist so you can track its share price against fair value and watch how the story develops. After you take a position, use the Portfolio Command Center to cut through market noise and receive focused, actionable updates on your holdings. For a longer term view, tap into the crowd wisdom inside our Community and see how other investors are thinking about Sihuan Pharmaceutical and similar stocks. By surfacing potential catalysts and risks early, Simply Wall St aims to help you act with confidence and stay ahead of the market.

Seeking Alternatives Beyond Sihuan Pharmaceutical?

Fresh ideas move fast. Some stocks are building breakout momentum while others get caught dropping off radars. Scan under the radar for now opportunities before the crowd notices and act now.

• Spot cash generative companies that still look overlooked by the market and review the curated 276 high quality undervalued stocks while the gap between price and fundamentals still matters.
• Capture potential compounding income streams by scanning the curated 411 dividend fortresses before yields or entry prices move away from levels that currently look appealing.
• Ride long term infrastructure themes by checking the hand picked 92 nuclear energy infrastructure stocks while many investors remain focused elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com